Information Provided By: 
Fly News Breaks for February 20, 2020
PTCT
Feb 20, 2020 | 07:40 EDT
RBC Capital analyst Brian Abrahams downgraded PTC Therapeutics to Sector Perform from Outperform with a price target of $60, down from $63. The analyst says that following an 80% run-up in its price, the valuation on the stock now more fairly reflects the potential of risdiplam and the longer-term promise for GT-AADC, along with its gene therapy franchise and stable DMD business, when balanced against its commercial and clinical risks.
News For PTCT From the Last 2 Days
There are no results for your query PTCT
